{"id":"NCT02551159","sponsor":"AstraZeneca","briefTitle":"Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer","officialTitle":"A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-15","primaryCompletion":"2020-07-06","completion":"2021-05-21","firstPosted":"2015-09-16","resultsPosted":"2021-10-13","lastUpdate":"2021-10-13"},"enrollment":823,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Squamous Cell Carcinoma of the Head and Neck"],"interventions":[{"type":"BIOLOGICAL","name":"MEDI4736","otherNames":[]},{"type":"BIOLOGICAL","name":"Tremelimumab","otherNames":[]},{"type":"BIOLOGICAL","name":"MEDI4736+Tremelimumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Cetuximab","otherNames":[]},{"type":"DRUG","name":"5-fluorouracil (5FU)","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]}],"arms":[{"label":"Monotherapy","type":"EXPERIMENTAL"},{"label":"Combination Therapy","type":"EXPERIMENTAL"},{"label":"Standard of Care","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease.","primaryOutcome":{"measure":"Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)","timeFrame":"From date of randomization until time of final analysis, an average of approximately 4 years","effectByArm":[{"arm":"Durvalumab + Tremelimumab","deltaMin":162,"sd":null},{"arm":"Durvalumab","deltaMin":84,"sd":null},{"arm":"Standard of Care (SOC)","deltaMin":77,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.787"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":197,"countries":["United States","Austria","Belgium","Brazil","Canada","France","Germany","Greece","India","Italy","Japan","Philippines","Poland","Romania","Russia","Slovakia","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["38430375","33684371"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419LC00001&amp;attachmentIdentifier=b4025180-dfd4-4783-a723-cba099a5d9fb&amp;fileName=D419LC00001_-_Protocol_v12__-redact.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419LC00001&amp;attachmentIdentifier=0a933c97-43c4-4fdc-8e9f-af78f3808b67&amp;fileName=D419LC00001_-_SAP_v7,0_-_redact.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419LC00001&amp;attachmentIdentifier=da78c143-9577-4556-a890-e24f765e4d5f&amp;fileName=D419LC00001_-_CSR_Synposis_-_28Apr2021-redact.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":168,"n":408},"commonTop":["Fatigue","Anaemia","Rash","Diarrhoea","Nausea"]}}